Patients with rare diseases and infections caused by multidrug‑resistant (MDR) bacteria often lack effective, convenient therapeutic options. In particular, complicated urinary tract infections (cUTIs) require intravenous antibiotics, leading to prolonged hospital stays and higher healthcare costs. The scarcity of oral agents that can address MDR pathogens leaves clinicians with limited treatment pathways.
Funding
$9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
GFounders
Product
Problem
Patients with rare diseases and infections caused by multidrug‑resistant (MDR) bacteria often lack effective, convenient therapeutic options. In particular, complicated urinary tract infections (cUTIs) require intravenous antibiotics, leading to prolonged hospital stays and higher healthcare costs. The scarcity of oral agents that can address MDR pathogens leaves clinicians with limited treatment pathways.
Solution
Spero Therapeutics focuses on developing differentiated small‑molecule antibiotics that address high‑unmet‑need indications. Its lead candidate, tebipenem HBr, is an oral carbapenem designed to treat cUTIs, including pyelonephritis, potentially reducing inpatient therapy duration. The program leverages a proprietary medicinal chemistry platform to create agents with activity against resistant Gram‑negative organisms. Successful Phase 3 data from the PIVOT‑PO trial demonstrated efficacy and safety, positioning tebipenem as the first oral carbapenem for this indication in the U.S. Additional pipeline assets (e.g., SPR206, SPR720) target other MDR bacterial infections using novel mechanisms of action. Strategic collaborations, such as the partnership with GSK, accelerate development and broaden access to these therapies.
Target Audience
Primary customers are infectious disease physicians, hospital antimicrobial stewardship programs, and specialty clinics that manage rare diseases and MDR bacterial infections. Payers and health systems seeking cost‑effective outpatient antibiotic solutions also constitute a key market segment.
Features
- Oral carbapenem formulation (tebipenem HBr) with high bioavailability for cUTI treatment
- First-in-class oral carbapenem indication in the United States, enabling outpatient management
- Phase 3 PIVOT‑PO trial met primary endpoint, supporting regulatory submission and market entry
- Broad-spectrum activity against carbapenem‑resistant Enterobacterales and other MDR Gram‑negative pathogens
- Proprietary scaffold optimization platform that enhances potency while minimizing toxicity
- Additional pipeline candidates (SPR206, SPR720) employing distinct mechanisms to overcome resistance
- Collaborative development model with major pharma partner (GSK) for shared resources and accelerated timelines
- Integrated pharmacokinetic/pharmacodynamic (PK/PD) modeling to support dose optimization and stewardship guidelines